Alpine Immune Sciences Inc
F:34LA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Alpine Immune Sciences Inc
F:34LA
|
US |
|
A
|
Abasca Resources Inc
XTSX:ABA
|
CA |
|
Adyen NV
OTC:ADYEY
|
NL |
|
Deutsche Post AG
F:DPWA
|
DE |
|
F
|
Forvia SE
XMUN:FAU
|
FR |
|
Lumentum Holdings Inc
NASDAQ:LITE
|
US |
|
Ferrovial SA
MAD:FER
|
ES |
|
KDDI Corp
F:DIP
|
JP |
|
Polyplex Corp Ltd
NSE:POLYPLEX
|
IN |
|
Eni SpA
NYSE:E
|
IT |
|
V
|
Vienna Insurance Group AG Wiener Versicherung Gruppe
F:WSV2
|
AT |
|
I
|
Italtile Ltd
JSE:ITE
|
ZA |
|
Pexip Holding ASA
OSE:PEXIP
|
NO |
|
Oric Pharmaceuticals Inc
NASDAQ:ORIC
|
US |
|
Findi Ltd
ASX:FND
|
AU |
|
Polycab India Ltd
NSE:POLYCAB
|
IN |
|
S
|
Schlumberger NV
XHAM:SCL
|
US |
|
Meta Platforms Inc
NASDAQ:META
|
US |
|
Pliant Therapeutics Inc
NASDAQ:PLRX
|
US |
|
Arabian Centres Company SJSC
SAU:4321
|
SA |
|
A
|
AXA SA
F:AXA
|
FR |
|
Heineken NV
AEX:HEIA
|
NL |
|
Thalassa Holdings Ltd
LSE:THAL
|
VG |
|
W
|
Westport Fuel Systems Inc
NASDAQ:WPRT
|
CA |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 34LA's stock price target?
Not Available
34LA does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Alpine Immune Sciences Inc?
Projected CAGR
-15%
Over the last 8 years, the compound annual growth rate for Revenue has been 82%. The projected CAGR for the next 1 year is -15%.